

	Satya-Murti	Baker	Bozic	Darling	Davis	Jarvick	Kendig	Kim	Lewis	McDonough	Schwartz	Sloan	Steinbrook	Juhn	Kirkpatrick	Rao	Voting Member Average	Overall Average
1	<i>1. How confident are you that there is adequate evidence to determine whether or not the use of BMPs in each of the following indications improves at least one of the clinically meaningful health outcomes?</i>																	
	<i>1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence</i>																	
A. On-label use in Lumbar spine (FDA Ref. LS and LS HDE) PMA	4	4	4	4	3	3	3	3	4	3	4	4	4	4	3	4	3.62	3.63
HDE	2	2	2	2	2	1	1	1	2	1	1	2	2	1	2	2	1.62	1.63
2. open tibial fracture (FDA Ref. T)	3	3	3	3	4	4	3	3	4	3	4	4	3	4	3	2	3.38	3.31
3. Recalcitrant long bone nonunions (FDA Ref. LB)	2	2	2	2	2	1	2	2	2	2	2	2	2	2	2	2	1.92	1.94
B. Off-label use in																		
1. Cervical spine	4	3	4	3	3	3	2	3	3	2	2	2	3	1	1	3	2.85	2.63
2. Lumbar spine	1	3	4	3	2	3	3	3	3	2	2	4	3	4	2	3	2.77	2.81
3. All other	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1.00	1.06

Note: Questions 2-6 should be addressed only for those indications where the panel is confident that there is adequate evidence (mean vote of 2.5) to consider the question.		Satya-Murti	Baker	Bozic	Darling	Davis	Jarvick	Kendig	Kim	Lewis	McDonough	Schwartz	Sloan	Steinbrook	Juhn	Kirkpatrick	Rao	Voting Member Average	Overall Average
2	<i>2. How confident are you that there is adequate evidence to determine that the use of BMPs in the lumbar spine for each of the indications identified below improves at least one of the clinically meaningful health outcomes?</i>																		
	<i>1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence</i>																		
	A. FDA PMA on-label use (FDA Ref. LS)	4	4	3	3	3	2	3	4	4	3	4	4	3	5	3	4	3.38	3.50
	*B. FDA HDE on-label use (FDA Ref. LS HDE)																		
	C. Off-label use	1	2	3	1	2	1	2	3	2	2	2	3	2	4	2	1	2.00	2.06

* No vote taken for question 2B.

Note: Questions 2 -6 should be addressed only for those indications where the panel is confident that there is adequate evidence (mean vote of 2.5) to consider the question.		Satya-Murti	Baker	Bozic	Darling	Davis	Jarvick	Kendig	Kim	Lewis	McDonough	Schwartz	Sloan	Steinbrook	Juhn	Kirkpatrick	Rao	Voting Member Average	Overall Average	
3	<i>3. How confident are you that the evidence is adequate to conclude that the use of BMPs for FDA HDE on-label use in recalcitrant long bone non-unions improves at least one of the clinically meaningful health outcomes? (FDA Ref. LB)</i>																			
	<i>1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence</i>																			
																		#DIV/0!	#DIV/0!	#DIV/0!

No vote taken for question 3.

| |

Note: Questions 2-6 should be addressed only for those indications where the panel is confident that there is adequate evidence (mean vote of 2.5) to consider the question.	Satya-Murti	Baker	Bozk	Darling	Davis	Jarvick	Kendig	Kim	Lewis	McDonough	Schwartz	Sloan	Steinbrook	Jahn	Kirkpatrick	Rao	Voting Member Average	Overall Average
4 <i>4. How confident are you that the evidence is adequate to conclude that the use of BMPs for FDA PMA approved on-label use for the treatment of acute, open tibial fractures improves at least one of the clinically meaningful health outcomes? (FDA Ref: T)</i>																		
<i>1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence</i>	3	3	3	4	4	3	4	4	4	3	4	4	3	5	3	2	3.54	3.50

| |

Note: Questions 2-6 should be addressed only for those indications where the panel is confident that there is adequate evidence (mean vote of 2.5) to consider the question.		Satya-Murti	Baker	Bozk	Darling	Davis	Jarvick	Kendig	Kim	Lewis	McDonough	Schwartz	Sloan	Steinbrook	Juhn	Kirkpatrick	Rao	Voting Member Average	Overall Average	
5	5. How confident are you that the evidence is adequate to conclude the off-label use of BMPs in the cervical spine improves at least one of the clinically meaningful health outcomes?																			
	1 Low Confidence Confidence -4- 2- 3 Intermediate 5 High Confidence																			
		1	1	1	1	1	1	2	1	1	2	1	1	1	1	1	1	1	1.15	1.13

1

Note: Questions 2-6 should be addressed only for those indications where the panel is confident that there is adequate evidence (mean vote of 2.5) to consider the question.		Satya-Murti	Baker	Bozic	Darling	Davis	Jarvick	Kendig	Kim	Lewis	McDonough	Schwartz	Sloan	Steinbrook	Juhn	Kirkpatrick	Rao	Voting Member Average	Overall Average
6	<i>How confident are you that these conclusions are generalizable to:</i>																		
	<i>1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence</i>																		
	A. The Medicare patient population?	2	2	1	2	1	2	3	3	4	2	2	3	2	3	2	2	2.23	2.25
	B. Community based settings?	2	3	2	2	2	2	2	2	2	3	4	4	3	2	2	2	2.54	2.44

| |